Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
ICR-led project awarded major funding to improve safety, transparency and public confidence around AI tools used in healthcare
The Institute of Cancer Research, London, is the joint recipient of a major new Medical Research Council (MRC) grant to advance how sensitive medical imaging data can be used for research.
Study sets out clear recommendations for patient-reported outcomes in early cancer drug trials
New research presents clear guidelines on how patient-reported outcomes (PROs) can be used more effectively in early-stage cancer drug trials, helping ensure that patient experiences meaningfully informed treatment decisions around dosing.
ICR welcomes NICE recommendation of talazoparib for advanced prostate cancer
The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in combination with enzalutamide, for adults with prostate cancer that has spread.
Breast cancer blood test can predict treatment response
A blood test can predict how well patients with advanced breast cancer will respond to targeted therapies – before treatment begins, according to new research.